Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that the Company received written agreement from the US FDA under a Special Protocol Assessment (SPA) for the design of GATHER2.